A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

ImmunoGen Inc.

About ImmunoGen Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics.

ImmunoGen's TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Antibodies with or without anticancer activity can become potent cancer-killing agents with TAP technology.


Pieline for Immunogen



HuN901-DM1, developed by ImmunoGen -- treatment of cancers that express the antigen CD56. These include small-cell lung cancer (SCLC), other cancers of neuroendocrine origin, and certain hematologic malignancies.

MLN2704, developed by Millennium Pharmaceuticals --targets the prostate-specific membrane antigen (PSMA)

Cantuzumab mertansine, has completed Phase I testing --cancers that express the CanAg antigen. These include colorectal, pancreatic, and other gastrointestinal cancers, as well as many non-small-cell lung



More on Immunogen

Home Page

Key Statistics for Immunogen

Basic Chart for Immunogen

Analyst Opinion

Analysts Estimates


Biotech100 Index
What are the Requirements to be listed in the Biotech100 Index?
See the Biotech100 List

Sponsored Links

Clinical Trials
What is a Clinical Trial?
Phase I ,-- Phase II, -- PhaseIII
What is Randomized Control?
 What is a Double Blind Experiment?
What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
Small Cap Stocks
Stocks and Bonds
Biotech100 Index

Careers and Employment
Biotechnology and Pharmaceutical
What are the Fastest Growing Careers?




Copyright 2005 BIOTECH100.COM. All rights reserved.